# SPECIALTY QUANTITY LIMIT PROGRAM

# **OLUMIANT** (baricitinib)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

### **II. COVERED QUANTITIES**

Medication	Standard Limit	FDA-recommended dosing
Olumiant 1 mg tablet	30 tablets per 30 days	For moderate renal impairment: Reduce dose to 1 mg once daily.
Olumiant 2 mg tablet	30 tablets per 30 days	2 mg once daily

### III. REFERENCE


1. Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC; May 2018.

#### **DOCUMENT HISTORY**

Created: Specialty Clinical Development (CN) 06/2018

Revised: JC 06/2019 (annual-no changes), JC 11/2019 (added 1 mg) Reviewed: CDPR/ EPA 06/2018, JG 06/2019, CHART 11/21/2019

External Review: 06/2018, 09/2018



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

 $\ensuremath{\text{@}}$  2019 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of